Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke

Br J Haematol. 2008 Dec;143(5):734-7. doi: 10.1111/j.1365-2141.2008.07395.x.


Ischemic stroke is associated with leucocyte activation. Activated leucocytes release elastase, an enzyme that can degrade fibrinogen. Fibrinogen elastase degradation products (FgEDP) may serve as a specific marker of elastase proteolytic activity. In a case-control study of 111 ischemic stroke patients and 119 controls, significantly higher FgEDP levels were observed in cases than in controls, both in the acute phase and in the convalescent phase. Results were only slightly affected by adjustment for cardiovascular risk factors, C-reactive protein and fibrinogen. Our findings suggest that FgEDP might be involved in the pathogenesis of stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • C-Reactive Protein / analysis
  • Case-Control Studies
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Fibrinogen / analysis
  • Humans
  • Ischemic Attack, Transient / blood
  • Ischemic Attack, Transient / immunology
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Odds Ratio
  • Pancreatic Elastase / blood
  • Risk
  • Stroke / blood*
  • Stroke / enzymology
  • Stroke / immunology


  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • Fibrinogen
  • C-Reactive Protein
  • Pancreatic Elastase